PHOENIX, Nov. 16, 2016 /PRNewswire/ -- Creative Medical Technology Holdings (OTCQB:CELZ) announced today the formation of a wholly-owned subsidiary, AmnioStem LLC, focused on the development of therapeutic products derived from amniotic fluid stem cells. These stem cells are subject of issued US patent #7,569,385, which was licensed from the University of California, San Diego (UCSD). This type of stem cell is considered an adult stem cell since no fetal damage occurs during its extraction. Amniotic fluid stem cells have been demonstrated by scientists from independent research institutions to be effective in animal models of stroke 1, heart attack 2, liver failure 3, colitis 4, diabetes 5, emphysema 6, and kidney injury 7. An important activity of amniotic fluid stem cells is that cells derived from one person can be used to treat other people, making them "universal donor" stem cells. "To date, Creative Medical Technology Holdings has focused on developing therapies using stem cells derived from the same patient. This allows for personalized treatment of conditions such as erectile dysfunction, for which we are running a clinical trial, as well as male infertility, miscarriages, and female infertility, which we are in preclinical stages of development. Based on in-depth discussions with our Scientific Advisory Board and experts in the field, we have decided that amniotic fluid stem cells possess the ideal characteristics for us to select as our source of 'allogeneic' or 'universal donor' stem cells to develop for therapeutic applications," said Timothy Warbington, President & CEO of Creative Medical Technology Holdings. The amniotic fluid is the liquid that surrounds the fetus and provides nutrient and growth factor support for its development. Amniotic fluid is obtained from routine amniocentesis procedures and is regarded as medical waste.